VOYAGE 2

TREMFYA^® EFFICACY DATA IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
VOYAGE 2 RESULTS VS PLACEBO AND HUMIRA^® (adalimumab) REFLECTED THOSE ACHIEVED IN VOYAGE 1

View Study Design

VOYAGE 2: CO-PRIMARY
ENDPOINTS AT WEEK 16^1,2*
(GLOBAL ANALYSIS)

PASI 90

IGA 0/1

VOYAGE 2: MAJOR SECONDARY
ENDPOINT AT WEEK 16^2,3*
(GLOBAL ANALYSIS)

ss-IGA 0/1

VOYAGE 2: MAJOR SECONDARY
ENDPOINTS AT WEEK 24^{1,2^‡}
(NORTH AMERICAN ANALYSIS)

PASI 90

IGA 0/1

IGA 0

VOYAGE 2: MAJOR SECONDARY
ENDPOINT AT WEEK 16^{1,3^‡}
(NORTH AMERICAN ANALYSIS)

PASI 75

^*Based on the results of an analysis of the 115 global sites from VOYAGE 2 (including North American sites [ie, US and Canada]).

^†P<0.001 vs placebo.

^‡Based on the results of an analysis of 41 North American sites (US=31, Canada=10) from VOYAGE 2 that used US-licensed Humira®.

^§P=0.003.

^llP=0.005.

^¶P<0.001 vs Humira®.

^*Based on the results of an analysis of the 115 global sites from VOYAGE 2 (including North American sites [ie, US and Canada]).

^†P<0.001 vs placebo.

^‡Based on the results of an analysis of 41 North American sites (US=31, Canada=10) from VOYAGE 2 that used US-licensed Humira®.

^§P=0.003.

^llP=0.005.

^¶P<0.001 vs Humira®.

Nearly 9 Out of 10 Patients Who Achieved PASI 90 at Week 28 Maintained This Response at Week 48^1#

VOYAGE 2: PRESPECIFIED EXPLORATORY ENDPOINT—MAINTENANCE AND DURABILITY OF PASI 90 RESPONSE^1-3

View Study Design

^††Maintenance and durability of PASI 90 response at Week 48 was a prespecified exploratory endpoint that was not adjusted for multiplicity; P value is considered nominal.

Major secondary endpoint: Median time to loss of PASI 90 response was 15 weeks (23 weeks after last TREMFYA® dose) for patients at Week 28 who were re-randomized to placebo and withdrawn from TREMFYA^®1

Based on the results of an analysis of the 115 global sites from VOYAGE 2 (including North American sites [ie, US and Canada]).

The same patients may not have responded at each time point.

^#Patients randomized to TREMFYA® at Week 0 and who were PASI 90 responders at Week 28 were re-randomized to either continue treatment with TREMFYA® q8w (maintenance group) or receive placebo (withdrawal group).

References: 1. TREMFYA® (guselkumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc. 2. Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418-431. 3. Data on file. Janssen Biotech, Inc.

CONTRAINDICATIONS
TREMFYA^® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Infections
TREMFYA^® may increase the risk of infection. Treatment with TREMFYA^® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA^® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA^® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA^® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA^®. Initiate treatment of latent TB prior to administering TREMFYA^®. Monitor patients for signs and symptoms of active TB during and after TREMFYA^® treatment. Do not administer TREMFYA^® to patients with active TB infection.

Hypersensitivity Reactions
Serious hypersensitivity reactions have been reported with postmarket use of TREMFYA^®, some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA^® and initiate appropriate therapy.

Immunizations
Prior to initiating TREMFYA^®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA^®.

ADVERSE REACTIONS
Most common (≥1%) adverse reactions associated with TREMFYA^® include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

Please read the full Prescribing Information and Medication Guide for TREMFYA^®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v1

TREMFYA^® EFFICACY DATA IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
VOYAGE 2 RESULTS VS PLACEBO AND HUMIRA^® (adalimumab) REFLECTED THOSE ACHIEVED IN VOYAGE 1

Nearly 9 Out of 10 Patients Who Achieved PASI 90 at Week 28 Maintained This Response at Week 48^1#

IMPORTANT SAFETY INFORMATION

INDICATION

Do you want to continue to [extlink:external-url]?

TREMFYA® EFFICACY DATA IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASISVOYAGE 2 RESULTS VS PLACEBO AND HUMIRA® (adalimumab) REFLECTED THOSE ACHIEVED IN VOYAGE 1

Nearly 9 Out of 10 Patients Who Achieved PASI 90 at Week 28 Maintained This Response at Week 481#

Do you want to continue to [extlink:external-url]?

TREMFYA^® EFFICACY DATA IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
VOYAGE 2 RESULTS VS PLACEBO AND HUMIRA^® (adalimumab) REFLECTED THOSE ACHIEVED IN VOYAGE 1

Nearly 9 Out of 10 Patients Who Achieved PASI 90 at Week 28 Maintained This Response at Week 48^1#